Protara Therapeutics, Inc. — Operating Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/5f0ecf48-093e-45d7-8a11-eaee5eafdacf/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-64.5M | 2025-01-01 – 2025-12-31 | evidence 0001213900-26-025433 |
| FY 2024 | $-49.2M | 2024-01-01 – 2024-12-31 | evidence 0001213900-25-020368 |
| FY 2023 | $-43.6M | 2023-01-01 – 2023-12-31 | evidence 0001213900-24-021982 |
| FY 2022 | $-67.1M | 2022-01-01 – 2022-12-31 | evidence 0001213900-23-018373 |
| FY 2021 | $-47.5M | 2021-01-01 – 2021-12-31 | evidence 0001213900-22-011208 |
| FY 2020 | $-34.4M | 2020-01-01 – 2020-12-31 | evidence 0001213900-21-014709 |
| FY 2019 | $-7.8M | 2019-01-01 – 2019-12-31 | evidence 0001213900-21-014709 |
| FY 2018 | $-21.4M | 2018-01-01 – 2018-12-31 | evidence 0001171843-19-001687 |
| FY 2017 | $-30.4M | 2017-01-01 – 2017-12-31 | evidence 0001171843-18-001934 |
| FY 2016 | $-28.7M | 2016-01-01 – 2016-12-31 | evidence 0001171843-17-001555 |
| FY 2015 | $-20.9M | 2015-01-01 – 2015-12-31 | evidence 0001171843-16-008541 |
| FY 2014 | $-7.6M | 2014-01-01 – 2014-12-31 | evidence 0001171843-15-001528 |
| FY 2013 | $-7.1M | 2013-01-01 – 2013-12-31 | evidence 0001171843-15-001528 |
| FY 2012 | $-8.0M | 2012-01-01 – 2012-12-31 | evidence 0001171843-15-001528 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).